INNOVATIVE KEYS TO
HEALTH AND WELLBEING

THE INNOVATIVE KEYS
TO HEALTH AND WELLBEING

INNOVATIVE KEYS TO HEALTH AND WELLBEING

PROVIDING
VALUE-​​ADDED INNOVATIONS

OUR MISSION AND VISION

Innokeys vision is a world with innovative solution for health and wellbeing for everybody.

Our mission is to provide value-added innovations in biopharmaceuticals to become a global player with significant contributions in fulfilling unmet medical needs.

ABOUT US

Innokeys activities span from identification, acquisition, development and commercialization of suitable innovations. Innokeys also provides consulting and partnering services for the above activities

THE INNOVATIVE KEYS
TO HEALTH AND WELLBEING
INNOKEYS 2011

CORE VALUES

MAKING INNOVATION ACCESSIBLE

Innokeys activities span from identification, acquisition, development and commercialization of suitable innovations. Innokeys also provides consulting and partnering services for the above activities

READMORE >>

NEWS

  • August 2013: Nimotuzumab in MOGA Australia

    innokeys | December 6th, 2013

    Medical Oncology Group of Australia...

  • ASCO 2013 : Nimotuzumab Abstracts

    innokeys | December 6th, 2013

    Professor Dirk Strumberg from Germany (center, in blue suit), the principal investigator of phase IIB/IIIA nimotuzumab clinical trial on pancreatic cancer, in discussion with Ferdinand Bach, CEO of Oncoscience AG, the sponsor of the trial, as the other ASCO participants viewed the Poster...

  • Daiichi Sankyo Enrolls First Patient in Nimotuzumab Phase 3 Clinical Trials

    innokeys | December 6th, 2013

    Tokyo, Japan (April 25, 2013) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that the first patient has been enrolled in two pivotal phase 3 clinical trials of nimotuzumab (DE-766), a recombinant humanized monoclonal antibody targeting the Epidermal Growth Factor Re...